Dramina (dimenhydrinate) tablets 50 mg. №5


Manufacturer: Croatia

Prevention and elimination of nausea and vomiting due to manifestations of sea and air sickness, when using radiation therapy, medications and after surgery. Symptomatic treatment of Meniere’s disease and other vestibular disorders.



Dramina Storage
active substance: dimenhydrinate;

1 tablet contains dimenhydrinate 50 mg;

Dramina excipients: microcrystalline cellulose; magnesium stearate; lactose monohydrate;

povidone; crospovidone.

Dramina Dosage form

Main physical and chemical properties: round flat tablets of white color with chamfers and a dash on one side.

Pharmacotherapeutic group
Antihistamines for systemic use.

ATX code R06A A02.

Pharmacological properties

Dimenhydrinate belongs to ethanolamine derivatives. Dimenhydrinate is a blocker of H1-receptors, has antiemetic, sedative, antimuscarinic, antihistamine action. Reduces the excitability of the vomiting center of the central nervous system.


After oral administration, dimenhydrinate is rapidly absorbed. The maximum concentration in blood plasma is reached in 15-30 minutes after reception and remains within 4-6 hours.

Approximately 98–99% of dimenhydrinate is bound to plasma proteins. Dimenhydrinate

passes through the placental barrier and enters breast milk.

The metabolism of dimenhydrinate is carried out mainly in the liver. Excreted from the body

within 24 hours, mainly in the form of metabolites, in smaller quantities – unchanged

in the form of kidneys. The half-life from blood plasma is almost 5-10 hours.

Prevention and elimination of nausea and vomiting due to the manifestations of seasickness and air sickness, with the use of radiation therapy, drugs and after surgery.
Symptomatic treatment of Meniere’s disease and other disorders of the vestibular apparatus.

Hypersensitivity to dimenhydrinate and to other antihistamines of a similar structure or to any of the excipients.

Angle-closure glaucoma, increased intracranial pressure, pheochromocytoma, porphyria, prostatic hyperplasia with delayed urination, convulsions (eclampsia, epilepsy), acute asthma attack, severe hepatic failure, severe renal insufficiency (clearance of children) years.

Interaction with other medicinal products and other forms of interaction
Concomitant use of alcohol with dimenhydrinate should be avoided, as the effect of dimenhydrinate may change and increase.

Dimenhydrinate may potentiate the anticholinergic effects of other drugs (eg, atropine, antiparkinsonian drugs, tricyclic antidepressants) and the central nervous system (CNS) inhibitory effect of drugs such as barbiturates, hypnotics, sedatives, tranquilizers, antidepressants, antidepressants. , drugs for substitution therapy), benzodiazepines, neuroleptics, antihypertensive drugs of central action, baclofen, thalidomide.

The drug may increase the CNS depressant effect of antiepileptic drugs.

Concomitant use with monoamine oxidase inhibitors (MAOIs) may increase the anticholinergic effect of dimenhydrinate; in some cases, paralytic syndrome (sometimes life-threatening), urinary retention, increased intraocular pressure, lowering of blood pressure, sedative effect on the central nervous system and respiratory disorders have been reported.

The drug enhances the effect of diazepam, leads to the opposite effect of amphetamines and their derivatives. Dimenhydrinate reduces the effectiveness of corticosteroid drugs and anticoagulants for oral administration.